Vol 22, No 4 (2016)
Review paper
Published online: 2017-03-14
Vascular changes in autoimmunological connective tissue diseases
DOI: 10.5603/AA.2016.0017
Acta Angiologica 2016;22(4):172-176.
Abstract
Vascular complications due to systemic connective tissue diseases pose a very difficult clinical problem. Due to the nature and location of the lesions, they very often prevent revascularization procedures and the conservative treatment is usually insufficient, which leads to a growth in the degree of ischemia and the need to amputate the limb. The authors clearly show the clinical picture of the most common diseases in this group — systemic lupus erythomatosus, systemic scleroderma, dermatomyositis, mixed connective tissue disease and Sjögren’s syndrome.
Keywords: connective tissue diseasevascular changessystemic sclerosisRaynaud’s fenomenon
References
- Bologna JL, Joriyyo JL, Schaffer JV. Dermatology. Third Edition Chapter. 2012; 7: 603–614.
- Hildebrand B; Chief Editor: Herbert S Diamond, MD. Undifferentiated Connective-Tissue Disease. Medscape. http://emedicine.medscape.com/article/334482-overview (16.04.2015).
- Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008; 37(4): 223–235.
- Yamamoto T, Eckes B, Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun. 2001; 281(1): 200–209.
- Eckes B, Mauch C, Hüppe G, et al. Control of fibrosis in systemic scleroderma. J Invest Dermatol. 1993; 100(1): 92S–96S.
- Szymańska E, Maj M, Rudnicka L. Twardzina układowa — przebieg kliniczny i możliwości terapeutyczne. Przegl Lek. 2005; 62: 1538–1541.
- Sicińska J, Szymańska E, Rudnicka L. Długotrwała terapia prostaglandyną E1 zmniejsza stwardnienia u pacjentów z twardziną układową — opis dwóch przypadków. Med Biol Sci. 2005; 19: 115–117.
- Sicińska J, Rudnicka L. Choroba Raynauda i objaw Raynauda w przebiegu kolagenoz. Pol Arch Med Wewn. 2002; 108: 1011–1022.
- Poormoghim H, Lucas M, Fertig N, et al. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000; 43(2): 444–451.
- Chung WS, Lin CL, Sung FC, et al. Systemic sclerosis increases the risks of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Rheumatology (Oxford). 2014; 53(9): 1639–1645.
- Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008; 358(9): 929–939.
- Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8): 2677–2686.
- LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2): 202–205.
- Black CM. Scleroderma--clinical aspects. J Intern Med. 1993; 234(2): 115–118.
- Wakata N, Kurihara T, Saito E, et al. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002; 41(11): 729–734.
- Sharma A, Dhooria A, Aggarwal A, et al. Connective Tissue Disorder-Associated Vasculitis. Current Rheumatology Reports. 2016; 18(6): 1–6.
- Frech TM, Shanmugam VK, Shah AA, et al. Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol. 2013; 31(2 Suppl 76): 166–171.
- Prete M, Fatone MC, Favoino E, et al. Raynaud's phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev. 2014; 13(6): 655–667.
- Denton CP, Hughes M, Gak N, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016; 55(10): 1906–1910.
- Sampaio-Barros PD, Zimmermann AF, Müller Cd, et al. Systemic Sclerosis Commission of the Brazilian Society of Rheumatology. Recommendations for the management and treatment of systemic sclerosis. Rev Bras Reumatol. 2013; 53(3): 258–275.
- Kowal-Bielecka O, Kuryliszyn-Moskal A. Guidelines/recommendations Systemic sclerosis. Reumatologia. 2016(Suppl 1): 51–55.
- Lasierra-Cirujeda J, Coronel P, Aza Mj, et al. Use of sulodexide in patients with peripheral vascular disease. J Blood Med. 2010; 1: 105–114.
- Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013; 8: 49–65.
- Vitiello M, Abuchar A, Santana N, et al. An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View. J Clin Aesthet Dermatol. 2012; 5(7): 33–43.